Research output: Contribution to journal › Review article › peer-review
Alba Saenz de Villaverde Cortabarria, Laura Makhoul, Giovanna Lombardi, John Strouboulis, Eugene Oteng-Ntim, Panicos Shangaris
Original language | English |
---|---|
Article number | 624477 |
Pages (from-to) | 1 |
Number of pages | 13 |
Journal | Frontiers in Cell and Developmental Biology |
Volume | 8 |
DOIs | |
Accepted/In press | 23 Dec 2020 |
Published | 22 Jan 2021 |
Additional links |
fcell_08_624477.pdf, 1.64 MB, application/pdf
Uploaded date:22 Jan 2021
Version:Final published version
This article is an open access publication accessible to readers anywhere in the world.
Sickle Cell Disease (SCD) is an autosomal recessive disorder resulting from a β-globin gene missense mutation and is among the most prevalent severe monogenic disorders worldwide. Haematopoietic stem cell transplantation remains the only curative option for the disease, as most management options focus solely on symptom control. Progress in prenatal diagnosis and fetal therapeutic intervention raises the possibility of in utero treatment. SCD can be diagnosed prenatally in high-risk patients using chorionic villus sampling. Among the possible prenatal treatments, in utero stem cell transplantation (IUSCT) shows the most promise. IUSCT is a non-myeloablative, non-immunosuppressive alternative conferring various unique advantages and may also offer safer postnatal management. Fetal immunologic immaturity could allow engraftment of allogeneic cells before fetal immune system maturation, donor-specific tolerance and lifelong chimerism. In this review, we will discuss SCD, screening and current treatments. We will present the therapeutic rationale for IUSCT, examine the early experimental work and initial human experience, as well as consider primary barriers of clinically implementing IUSCT and the promising approaches to address them.
King's College London - Homepage
© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454